JAGX - Jaguar Health, Inc.
Jaguar Health, Inc.
200 Pine Street
Suite 400
San Francisco, CA 94104
United States
415 371 8300
https://jaguar.health
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 60
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Lisa A. Conte | Founder, CEO, Pres & Director | 771.4k | N/A | 1959 |
| Dr. Pravin R. Chaturvedi Ph.D. | Chief Scientific Officer & Chair of Scientific Advisory Board | 539.04k | N/A | 1963 |
| Mr. Jonathan S. Wolin CPA, J.D., M.B.A. | Chief of Staff, Chief Compliance Officer & Gen. Counsel | 520.29k | N/A | 1963 |
| Mr. Ian H. Wendt M.B.A. | Chief Commercial Officer | 441.31k | N/A | 1968 |
| Dr. Steven R. King Ph.D. | Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec. | 477.66k | N/A | 1958 |
| Ms. Carol R. Lizak M.B.A. | Chief Financial Officer | N/A | N/A | 1964 |
| Mr. Peter Hodge | Sr. Director of Investor Relations, Bus. Devel. & Special Events | N/A | N/A | N/A |
| Dr. Karen J. Brunke Ph.D. | Exec. VP of Corp. & Bus. Devel. | N/A | N/A | 1953 |
| Mr. David Sesin | Chief Manufacturing Officer | N/A | N/A | N/A |
Description
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.
Corporate Governance
Jaguar Health, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
